181 related articles for article (PubMed ID: 16000280)
1. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion.
Pinborg LH; Ziebell M; Frøkjaer VG; de Nijs R; Svarer C; Haugbøl S; Yndgaard S; Knudsen GM
J Nucl Med; 2005 Jul; 46(7):1119-27. PubMed ID: 16000280
[TBL] [Abstract][Full Text] [Related]
2. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
[TBL] [Abstract][Full Text] [Related]
3. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.
Ziebell M; Holm-Hansen S; Thomsen G; Wagner A; Jensen P; Pinborg LH; Knudsen GM
J Nucl Med; 2010 Dec; 51(12):1885-91. PubMed ID: 21078806
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT.
Ziebell M
Dan Med Bull; 2011 May; 58(5):B4279. PubMed ID: 21535991
[TBL] [Abstract][Full Text] [Related]
5. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain.
Halldin C; Erixon-Lindroth N; Pauli S; Chou YH; Okubo Y; Karlsson P; Lundkvist C; Olsson H; Guilloteau D; Emond P; Farde L
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1220-30. PubMed ID: 12811422
[TBL] [Abstract][Full Text] [Related]
6. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
[TBL] [Abstract][Full Text] [Related]
7. Quantification of [(123)I]PE2I binding to dopamine transporters with SPET.
Pinborg LH; Videbaek C; Svarer C; Yndgaard S; Paulson OB; Knudsen GM
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):623-31. PubMed ID: 11976800
[TBL] [Abstract][Full Text] [Related]
8. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline.
Schwarz J; Storch A; Koch W; Pogarell O; Radau PE; Tatsch K
J Nucl Med; 2004 Oct; 45(10):1694-7. PubMed ID: 15471835
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 4 methods for quantification of dopamine transporters by SPECT with [123I]IACFT.
Bonab AA; Fischman AJ; Alpert NM
J Nucl Med; 2000 Jun; 41(6):1086-92. PubMed ID: 10855640
[TBL] [Abstract][Full Text] [Related]
10. Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT.
Ziebell M; Thomsen G; Knudsen GM; de Nijs R; Svarer C; Wagner A; Pinborg LH
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):101-9. PubMed ID: 16896668
[TBL] [Abstract][Full Text] [Related]
11. Validation of a method for accurate and highly reproducible quantification of brain dopamine transporter SPECT studies.
Jensen PS; Ziebell M; Skouboe G; Khalid U; de Nijs R; Thomsen G; Knudsen GM; Svarer C
J Nucl Med Technol; 2011 Dec; 39(4):271-8. PubMed ID: 22072699
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study.
Jucaite A; Odano I; Olsson H; Pauli S; Halldin C; Farde L
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):657-68. PubMed ID: 16514530
[TBL] [Abstract][Full Text] [Related]
13. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies.
Koch W; Radau PE; Hamann C; Tatsch K
J Nucl Med; 2005 Jul; 46(7):1109-18. PubMed ID: 16000279
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging.
Kuikka JT; Baulieu JL; Hiltunen J; Halldin C; Bergström KA; Farde L; Emond P; Chalon S; Yu M; Nikula T; Laitinen T; Karhu J; Tupala E; Hallikainen T; Kolehmainen V; Mauclaire L; Maziere B; Tiihonen J; Guilloteau D
Eur J Nucl Med; 1998 May; 25(5):531-4. PubMed ID: 9575250
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans.
Frokjaer VG; Pinborg LH; Madsen J; de Nijs R; Svarer C; Wagner A; Knudsen GM
J Nucl Med; 2008 Feb; 49(2):247-54. PubMed ID: 18199621
[TBL] [Abstract][Full Text] [Related]
16. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
[TBL] [Abstract][Full Text] [Related]
17. A new model for separation between brain dopamine and serotonin transporters in 123I-beta-CIT SPECT measurements: normal values and sex and age dependence.
Ryding E; Lindström M; Brådvik B; Grabowski M; Bosson P; Träskman-Bendz L; Rosén I
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1114-8. PubMed ID: 15014902
[TBL] [Abstract][Full Text] [Related]
18. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK
Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells.
Page G; Chalon S; Emond P; Maloteaux JM; Hermans E
Neurochem Int; 2002 Feb; 40(2):105-13. PubMed ID: 11738476
[TBL] [Abstract][Full Text] [Related]
20. Quantification of 11C-MADAM binding to the serotonin transporter in the human brain.
Lundberg J; Odano I; Olsson H; Halldin C; Farde L
J Nucl Med; 2005 Sep; 46(9):1505-15. PubMed ID: 16157534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
